Karyopharm Therapeutics enters forbearance agreement and waiver on Sept 10, 2026 - SEC filing
KPTI•Forbearance agreement and missed debt payment
Sept. 11 (Reuters) - Karyopharm Therapeutics Inc. KPTI.O:
- Karyopharm Therapeutics enters forbearance agreement and waiver on Sept. 10, 2026 - SEC filing
- Karyopharm Therapeutics did not pay $15.80 million principal installment due Sept. 10, 2026 - SEC filing
- Karyopharm Therapeutics does not expect to pay cash interest due Sept. 30, 2026 - SEC filing
- Karyopharm Therapeutics agrees to pay $20 million in fees as forbearance consideration - SEC filing
- Karyopharm Therapeutics to pay fees in shares of newly created preferred stock - SEC filing
Source text: [ID:n0001193125-26-388621]
Further company coverage: KPTI.O
